Controlling Shareholder Randal J. Kirk Sells $15.6M in Precigen Stock, Reducing Stake
PGEN has more than doubled off its 52-week low of $1.11 on elevated volume (2.7× avg).
Summary
Randal J. Kirk, the controlling shareholder of Precigen, Inc., through affiliated entities, sold 4.77 million shares of common stock for approximately $15.6 million, reducing his beneficial ownership from approximately 37.2% to 35.9%.
Key Events · Ownership and Investor Activity · PGEN
-
Significant Share Sale
Entities controlled by Randal J. Kirk sold 4,772,781 shares of Precigen common stock in open market transactions on March 30, 2026.
-
Substantial Proceeds
The sale generated approximately $15,581,221 in net proceeds for the selling entities.
-
Reduced Ownership Stake
This transaction decreased Randal J. Kirk's beneficial ownership from approximately 37.2% to 35.9% of the company's outstanding shares (including exercisable derivatives).
Analysis · PGEN · Life Sciences
This Schedule 13D/A reports a significant disposition of shares by Randal J. Kirk, the company's controlling shareholder. The sale of over $15.5 million worth of stock, representing approximately 1.14% of the company's market capitalization, is a material event. While the filing notes Kirk's continued beneficial ownership of 35.9% (including exercisable warrants and options), this reduction in his stake could be interpreted by investors as a signal, especially following the recent 10-K filing which reported a substantial net loss for 2025. Investors will likely monitor future filings for further changes in insider holdings.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PGEN was trading at $3.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.11 to $5.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.